Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
156.54B
Market cap156.54B
Price-Earnings ratio
20.12
Price-Earnings ratio20.12
Dividend yield
6.30%
Dividend yield6.30%
Average volume
43.98M
Average volume43.98M
High today
$27.81
High today$27.81
Low today
$27.20
Low today$27.20
Open price
$27.25
Open price$27.25
Volume
21.06M
Volume21.06M
52 Week high
$27.94
52 Week high$27.94
52 Week low
$20.92
52 Week low$20.92

Stock Snapshot

Pfizer(PFE) stock is priced at $27.53, giving the company a market capitalization of 156.54B. It carries a P/E multiple of 20.12 and pays a dividend yield of 6.3%.

As of 2026-03-26, Pfizer(PFE) stock has fluctuated between $27.20 and $27.81. The current price stands at $27.53, placing the stock +1.2% above today's low and -1.0% off the high.

Pfizer(PFE) shares are trading with a volume of 21.06M, against a daily average of 43.98M.

In the last year, Pfizer(PFE) shares hit a 52-week high of $27.94 and a 52-week low of $20.92.

In the last year, Pfizer(PFE) shares hit a 52-week high of $27.94 and a 52-week low of $20.92.

PFE News

24/7 Wall St. 8h
Income Investors Face a Hard Truth About Pfizer's Payout Safety

Income Investors Face a Hard Truth About Pfizer’s Payout Safety By Trey Thoelcke Published Mar 26, 7:55AM EDT Quick Read Pfizer (PFE) paid $9.771B in dividend...

Income Investors Face a Hard Truth About Pfizer's Payout Safety
Simply Wall St 9h
Pfizer Lyme Vaccine Readout Adds New Angle To Valuation Debate

Pfizer and Valneva reported topline Phase 3 results for their experimental Lyme disease vaccine, showing over 70% efficacy but missing the primary statistical e...

Pfizer Lyme Vaccine Readout Adds New Angle To Valuation Debate
Nasdaq 21h
Is Pfizer Stock a Buy After This Win?

Key Points Pfizer's recent phase 2 win was encouraging, but not yet a slam dunk. The company could make significant clinical and regulatory progress in the ne...

Is Pfizer Stock a Buy After This Win?

Analyst ratings

55%

of 29 ratings
Buy
34.5%
Hold
55.2%
Sell
10.3%

More PFE News

24/7 Wall St. 1d
This 6.5%‑Yielding Dividend Payer is Sitting on a Breakthrough Investors Haven’t Priced In

This 6.5%‑Yielding Dividend Payer is Sitting on a Breakthrough Investors Haven’t Priced In By Joey Frenette Published Mar 25, 12:23PM EDT Quick Read Pfizer (P...

This 6.5%‑Yielding Dividend Payer is Sitting on a Breakthrough Investors Haven’t Priced In
Nasdaq 1d
Will the Recent Label Expansion of BMY's Opdivo Boost Its IO Franchise?

Bristol Myers Squibb BMY recently won FDA and European Commission (EC) approvals for the label expansion of its blockbuster immuno-oncology (IO) drug Opdivo. T...

Will the Recent Label Expansion of BMY's Opdivo Boost Its IO Franchise?
TipRanks 1d
Notable open interest changes for March 25th

Tuesday’s total option volume of 56.5 million contracts resulted in net open interest growth of 7.38 million calls and 5.85 million puts. fuboTV (FUBO), NVIDIA...

Simply Wall St 2d
A Look At Pfizer Valuation As Shares Trade Near Recent Levels

Advertisement Pfizer overview and recent share performance Pfizer (PFE) has been on investors’ radar recently, with the stock last closing at US$26.96 and sho...

A Look At Pfizer Valuation As Shares Trade Near Recent Levels
Nasdaq 2d
VALN Stock Nosedives on Mixed Results From Lyme Disease Vaccine Study

Shares of Valneva VALN tanked 37% on Monday after the company reported top-line results from the phase III VALOR study, which evaluated its experimental Lyme di...

VALN Stock Nosedives on Mixed Results From Lyme Disease Vaccine Study
24/7 Wall St. 2d
Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial

Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial By Joel South Published Mar 24, 10:52AM EDT Quick Read Pfizer (PFE...

Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial
TipRanks 2d
Pfizer price target raised to $36 from $35 at Guggenheim

Guggenheim raised the firm’s price target on Pfizer (PFE) to $36 from $35 and keeps a Buy rating on the shares. Topline data for Pfizer’s MEVPRO-1 Phase 3 trial...

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.